Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma

Yucai Wang, Han W. Tun, Betsy R. LaPlant, Rebecca L. King, Ivana N. Micallef, Madiha Iqbal, Allison C. Rosenthal, Stephen M. Ansell, Jose C. Villasboas Bisneto, Arushi Khurana, Gita Thanarajasingam, Thomas M. Habermann, Javier L. Munoz, Paul J. Hampel, Patrick B. Johnston, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2024) 144 (Supplement 1): 580.

https://doi.org/10.1182/blood-2024-200206

Published: 2024

Journal Articles

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2372.

https://doi.org/10.1182/blood-2024-210474

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Blood (2024) 144 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2024-201269

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Blood (2024) 144 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2024-204593

Published: 2024

Journal Articles

Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma

Cinnie Soekojo, Susan M. Geyer, Emmanuel Contreras Guzman, Kaitlyn Whitaker, Shaji Kumar, Vincent Rajkumar, Joselle Cook, Yogesh Chawla, Francis Buadi, Angela Dispenzieri, Moritz Binder, Rafael Fonseca, Taro Hitosugi, Dragan Jevremovic, Wilson I. Gonsalves, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 1880.

https://doi.org/10.1182/blood-2024-207440

Published: 2024

Journal Articles

Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study

Stefano Luminari, Jose C. Villasboas Bisneto, Geoffrey Chong, David Tucker, Srikanth Ambati, Chinjune Lin, Hesham Mohamed, C. Akunna Otele, Giovanni Antico, Ana Jiménez Ubieto

Blood (2024) 144 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2024-199100

Published: 2024

Journal Articles

Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study

John M. Burke, Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, Steven Liu, Juliana M.L. Biondo, Prachi Jani, Mei Wu, Yong Mun, Vivek S. Chopra, Jessica M. Grindheim, Dana Farinella, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 3008.

https://doi.org/10.1182/blood-2024-194604

Published: 2024

Journal Articles

Can I Cap the Prednisone? a Systematic Review and Meta-Analysis Comparing Fixed-Dose with Body Surface Area (BSA)-Adjusted Prednisone in Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

Lucas Villasboas de Oliveira, Ahmad AL-Jarrad, Raphael Mwangi, Christina Moe, Adrienne N. Nedved, Paul J. Hampel, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 7588.

https://doi.org/10.1182/blood-2024-210544

Published: 2024

Journal Articles

Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2024-200408

Published: 2024

Journal Articles

Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy

Deepa Jagadeesh, Silvana Novelli, Stefano Luminari, Michal Taszner, Michele Merli, Yingzxin Xu, Siddhesh Kamat, Liza Mastikhina, Srikanth Ambati, Jenny Chen, Keith Chan, Shannon Cope, Sam Keeping, Clyde Caisip, Hesham Mohamed, Aafia Chaudhry, James Harnett, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 7803.

https://doi.org/10.1182/blood-2024-200865

Published: 2024

Journal Articles

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2024-211111

Published: 2024

Journal Articles

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 7589.

https://doi.org/10.1182/blood-2024-210586

Published: 2024

Journal Articles

Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma

Jose C. Villasboas Bisneto, Pier Luigi Zinzani, Andrew J. Davies, Robert Kridel, Guilherme Fleury Perini, Parth Rao, Joanna Mikita-Geoffroy, Akshay Sudhindra, Charalambos Andreadis

Blood (2024) 144 (Supplement 1): 4422.2.

https://doi.org/10.1182/blood-2024-203181

Published: 2024

Journal Articles

High Dimensional Longitudinal Single-Cell Peripheral Blood Immune Monitoring in Lymphoma Reveals Skewed Monocyte and T Cell Profiles at Baseline Followed By Differential T-Cell Recovery in Patients Treated with Bendamustine

Ahmad AL-Jarrad, Kevin Pavelko, Kaitlyn Whitaker, Roberto Leon-Ferre, Cinnie Soekojo, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 6265.

https://doi.org/10.1182/blood-2024-210819

Published: 2024

Journal Articles

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 669.

https://doi.org/10.1182/blood-2023-181942

Published: 2023

Journal Articles

Bridging Radiotherapy for Patients with Limited (<5 Disease Sites) Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Prior to CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2127.

https://doi.org/10.1182/blood-2023-186806

Published: 2023

Journal Articles

Healthcare Utilization Outcomes of Outpatient CAR-T Cell Therapy with Remote Patient Monitoring Program

Blood (2023) 142 (Supplement 1): 5075.

https://doi.org/10.1182/blood-2023-187834

Published: 2023

Journal Articles

Cellular Interactions within Clonal Dendritic Cell Aggregates Drive Immune Tolerance in Chronic Myelomonocytic Leukemia Bone Marrow Microenvironment

Abhishek A Mangaonkar, Terra L Lasho, Justin Boysen, Christy M Finke, Jenna A. Fernandez, Jose. C. Villasboas, Christopher Dean, Alejandro Ferrer, Moritz Binder, Liguo Wang, Jeong-Heon Lee, Kaaren K. Reichard, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2023-186856

Published: 2023

Journal Articles

The Impact of Pre-Existing Autoimmune Disease on the Safety and Efficacy of CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2023-188155

Published: 2023

Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Blood (2023) 142 (Supplement 1): 3041.

https://doi.org/10.1182/blood-2023-181650

Published: 2023

NARROW

A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma

Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study

Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study

Can I Cap the Prednisone? a Systematic Review and Meta-Analysis Comparing Fixed-Dose with Body Surface Area (BSA)-Adjusted Prednisone in Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma

Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma

High Dimensional Longitudinal Single-Cell Peripheral Blood Immune Monitoring in Lymphoma Reveals Skewed Monocyte and T Cell Profiles at Baseline Followed By Differential T-Cell Recovery in Patients Treated with Bendamustine

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Bridging Radiotherapy for Patients with Limited (<5 Disease Sites) Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Prior to CAR T-Cell Therapy

Healthcare Utilization Outcomes of Outpatient CAR-T Cell Therapy with Remote Patient Monitoring Program

Cellular Interactions within Clonal Dendritic Cell Aggregates Drive Immune Tolerance in Chronic Myelomonocytic Leukemia Bone Marrow Microenvironment

The Impact of Pre-Existing Autoimmune Disease on the Safety and Efficacy of CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only